SMS Pharmaceuticals Ltd Financials
Company Logo

SMS Pharmaceuticals Ltd Financial Statement

SMS Pharmaceuticals Ltd Income Statement

Quarterly

Annual

*All values are in Rs. Cr

Particulars
Sep 2024
Revenue198.05
Operating Expense164.89
Net Profit14.26
Net Profit Margin7.20
Earning Per Share1.68
EBIDTA32.19
Effective Tax Rate14.17
Invest in SMS Pharmaceuticals Ltd
₹0 Brokerage*
Open Demat Account
*By signing up you agree to our Terms and Conditions

SMS Pharmaceuticals Ltd Profit & Loss

*All values are in Rs. Cr

Standalone

Consolidated

Particulars
Mar 2024
Total Revenue Annual709.26
Operating Expenses Annual592.42
Operating Profit Annual121.30
Interest Annual23.46
Depreciation30.01
Net Profit Annual49.42
Tax Annual16.91

SMS Pharmaceuticals Ltd Cash Flow

*All values are in Rs. Cr

Standalone

Consolidated

Particulars
Mar 2024
Cash Flow at the Beginning7.31
Cash Flow from Operations50.12
Cash Flow from Investing-52.07
Cash Flow from Financing30.68
Cash Flow at the End36.04

SMS Pharmaceuticals Ltd Key Ratios

*All values are in Rs. Cr

Standalone

Consolidated

Particulars
Mar 2024
PBDIT Margin (%)16.14
PBIT Margin (%)11.95
PBT Margin (%)11.44
Net PROFIT Margin (%)6.57
Return On Networth / Equity (%)9.28
Return On Networth /Employed (%)11.22
Return On Assets (%)6.17
Total Debt / Equity (X)0.50
Asset Turnover Ratio (%)0.94

SMS Pharmaceuticals Ltd Balance Sheet

*All values are in Rs. Cr

Standalone

Consolidated

Particulars
Mar 2024
Fixed Assets Annual437.26
Total Current Assets Annual533.89
Non Current Assets Annual534.36
Total Shareholders Funds Annual570.49
Total Assets Annual1,068.25

SMS Pharmaceuticals Ltd Earning Calls

EPS (INR)

Expected

1.66

Reported

1.67

Surprise

0.60%

Jun 2024

EPS beaten by 0.60%

Mar 2024

EPS beaten by 0.00%

Dec 2023

EPS beaten by 0.00%

Get Your FAQs Right

As of Nov 23, 2024, SMS Pharmaceuticals Ltd has a market capitalization of 1,507.23 Cr. Value Research classifies it as a Small-Cap company.
Yes, SMS Pharmaceuticals Ltd is debt-free with a debt-to-equity ratio of 0.49.
In FY 2023 , SMS Pharmaceuticals Ltd recorded a total revenue of approximately 709.26 Cr marking a significant milestone in the company's financial performance.
SMS Pharmaceuticals Ltd's Future outlook anticipates robust growth, with forecasted earnings and revenue rising approximately 0.3% and 0.2% annually, respectively..
SMS Pharmaceuticals Ltd's current PE ratio is 30.50.
SMS Pharmaceuticals Ltd's ROCE averaged 8.6% from the FY ending March 2022 to 2024, with a median of 10.5%. It peaked at 11.6% in March 2022, reflecting strong capital efficiency over the period..
SMS Pharmaceuticals Ltd's latest EBIT is Rs. 89.79 Cr, surpassing the average EBIT of Rs. 68.26 Cr over the 5 years..